Monteris Medical Inc. has raised $3.4 million in equity for a device that enables minimally invasive laser surgery for brain tumors, according to a filing with the Securities and Exchange Commission.
Monteris hopes to stretch the funding round to about $4.5 million, CEO Jim Duncan said. The 25-employee company has garnered $21 million in investment funding since its inception in 1999.
Monteris’ AutoLITT System received clearance for use in neurosurgery from the Food and Drug Administration last year. The AutoLITT procedure uses an MRI to guide a laser that allows doctors to watch and adjust as they heat glioblastoma multiforme (GBM) tumors, reduce them to a pasty state and remove the tumor.
Health Executives on Digital Transformation in Healthcare
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
The AutoLITT combines three technologies: a laser-induced thermal therapy, real-time MRI heat monitoring and minimally invasive MRI-guided surgical procedures.
Monteris plans to use the capital to fund its sales operations, Duncan said. The company just made its first two sales of the AutoLITT to Cleveland Clinic and University Hospitals Case Medical Center. Doctors at both hospitals collaborated on the first human trials of the device. Monteris has three employees on its sales team, Duncan said.
The AutoLITT System offers an alternative to patients with brain tumors that are too risky to treat, or don’t respond to other forms of treatment, according to Monteris.
The funding was sourced from four investors, three of which are based in Canada. Monteris’ two major investors are both Canadian — Western Life Science Venture Fund and the venture arm of Business Development Bank of Canada. Growthworks is Monteris’ third Canadian investor.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Monteris has offices in Kalamazoo, Mich. and Winnipeg, Canada. Monteris added the Michigan office in 2008, after it received (pdf) an unspecified investment from the Southwest Michigan First Life Sciences Fund, which was the fourth investor in the company’s most recent fundraise. Monteris’ technology is based on research performed at the University of Manitoba in Winnipeg.
Duncan said the company has identified other potential applications of its technology besides brain tumors, but declined to specify them.